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Following the encouraging report of the Edmonton group, there was a rejuvenation of the islet transplantation ﬁeld. After that,
more pessimistic views spread when long-term results of the clinical outcome were published. A progressive loss of the β-cell
function meant that almost all patients were back on insulin therapy after 5 years. More than 10 years ago, we demonstrated that
amyloid deposits rapidly formed in human islets and in mouse islets transgenic for human IAPP when grafted into nude mice. It
is, therefore, conceivable to consider amyloid formation as one potential candidate for the long-term failure. The present paper
reviewsattemptsinourlaboratoriestoelucidatethedynamicsofandmechanismsbehindtheformationofamyloidintransplanted
islets with special emphasis on the impact of long-term hyperglycemia.
Copyright © 2008 Arne Andersson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
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1. INTRODUCTION
The discovery of insulin in the early 1920s greatly improved
the prognosis for type 1 diabetes patients and by such
means patients with diabetes could survive a previously
fatal disease. Because of the substantial improvements in
insulin therapy, most patients nowadays can handle their
treatment themselves and risks for the crippling long-
t e r mc o m p l i c a t i o n sh a v eb e c o m ee x t e n s i v e l yr e d u c e d .T h i s ,
however, requires strict blood glucose control and life
style restrictions. These latter insuﬃciencies of the present
treatment together with the fact that a subgroup of patients
is still disturbed by frequent hypoglycaemic attacks have
meant that there is considerable interest in pancreatic islet
transplantation. For long replacement of the destroyed β-
cells in type 1 diabetes with new β-cells, this has attracted
much attention. Paul Lacy’s pioneering work with his
collagenase-based method for rat islet isolation paved the
way for islet transplantation experiments. Clinical trials
were carried out in the 80s and 90s but only about 10%
of islet recipients achieved normoglycemia without insulin
therapy. However, in their report in the year 2000 James
Shapiro et al. reported a handful of diabetes patients all of
whom became normoglycemic after two or three intraportal
implantations of noncultured human islets [1]. Given a
steroid-free immunosuppression, these patients remained
oﬀ insulin for at least one year. In an international trial
of this so-called Edmonton protocol, 36 subjects with
type 1 diabetes underwent this type of treatment at nine
international sites [2]. While 16 of them (44%) were insulin
free after one year only 5 (14%) remained so after one more
year. It was concluded that there was a progressive loss of
islet function in most subjects, who had all become insulin
independent initially.
For long, it has been postulated that long-term hyper-
glycemia might inﬂuence β-cell function in a negative way.
Numerous in vitro and in vivo studies have indicated
that so is the case but the molecular mechanisms are still
unclear. We, therefore, found it conceivable to consider
amyloid formation as one potential candidate. This paper
reviews attempts in our laboratory to elucidate the fate
of transplanted human islets with a special view on their
morphology and function and especially so under inﬂuence
of prolonged hyperglycemic stress.2 Experimental Diabetes Research
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Figure 1: Processing at double basic amino acid residues of proinsulin and proIAPP by the prohormone convertases PC 1/3 and PC2.
2. ISLET AMYLOID POLYPEPTIDE AND
ISLET AMYLOID
Although islet amyloid was discovered already in 1901 [3, 4],
its impact in the pathogenesis of type 2 diabetes has been
questioned for a long period of time. However, there are
several lines of evidence for the importance of the amyloid
formationfortheβ-celllesionintype2diabetes(forreviews,
see [5, 6]). The exact mechanisms are still not very well
understood but aggregated IAPP is toxic to β-cells [7, 8].
IAPP was discovered by puriﬁcation and analysis of
amyloid, ﬁrst from a human insulinoma [9, 10] and later
from islets of Langerhans [11, 12] .T h es a m ep e p t i d ew a s
found to form amyloid in apes [13, 14] and cats [11, 15].
Human IAPP is a 37-amino acid residue peptide, expressed
as a prepromolecule. After removal of the signal peptide,
the 67-amino acid propeptide is further processed at two
double basic residues by the prohormone convertases PC2
and PC1/3 which remove two short peptides N- and C-
terminally (Figure 1). The remaining peptide is C-terminally
amidated and there is a disulﬁde bridge between residues 2
and 7.
IAPP is expressed by β-cells and is stored and released
together with insulin. IAPP is very aggregation-prone in
vitro and rapidly forms amyloid-like ﬁbrils. This does not
normally happen in vivo, where there must be mechanisms
which hinder this. Binding to insulin may be such a
mechanism[16,17].However,itisnotunderstoodwhyIAPP
aggregates into amyloid in conjunction with type 2 diabetes.
Experiments with transgenic mice, overexpressing human
IAPP, clearly indicate that an increased production of IAPP
is not the single explanation but that other factors must
contribute.
2.1. TransgenicanimalsoverexpressinghumanIAPP
Mice and rats do not develop islet amyloid, depending on
diﬀerences in the IAPP sequence. Proline residues in the
amyloid-forming core of IAPP abolish the ﬁbril formation
in both species [18]. Several groups have, therefore, created
transgenic mouse lines expressing human IAPP under
regulation of an insulin promoter. In spite of overexpression
of human IAPP, islet amyloid generally does not develop.
However, amyloid does appear when such animals are fed
a diet high in fat [19, 20] or are crossed with ob/ob [21]
or agouti [22] mice. We are working with a mouse line,
overexpressing human IAPP behind rat insulin 1 promoter
but devoid of mouse IAPP. Animals of this strain do not
spontaneously develop islet amyloid at any age but in male
mice, when fed a diet with high content of fat, amyloid
deposits occur at an age of 11 months [20]. The amyloid
is mainly found extracellularly but intracellular deposits do
occur [23].
2.2. Amyloiddevelopmentinculturedhumanand
transgenicmouseislets
Interestingly, isletsisolatedfromourtransgenicmousestrain
develop amyloid deposits rapidly when cultured in vitro
[24]. A similar experience was obtained with another human
IAPP transgenic mouse strain [25]. Furthermore, in contrast
to what is found in islets in type 2 diabetes, where the
amyloid is extracellular [26], intracellular aggregation of
IAPP initially takes place in cultured human islets [27].
The exact compartmental position has been diﬃcult to
determine but is probably the endoplasmic reticulum or
Golgi apparatus [28].
2.3. Aberrantprocessingandamyloidformation
There is evidence that the intracellular amyloid contains
proIAPP and a defect processing of this precursor to
mature IAPP may play a role in the pathogenesis of
amyloid formation [23]. β-Cell stress that occurs in the
initial phase of type 2 diabetes results in a disproportional
secretion of unprocessed or partially processed proinsulin
(des 32-33 C-peptide-A-chain fragment) [29]. This shift
can mirror an increase in granule turnover, or, perhaps
more interestingly is a sign of incomplete processing due to
convertase deﬁciency. Also the prohormone convertases PC
1/3 and PC2 themselves must undergo cleavage to become
active, and therefore, aberrant activation of convertases canArne Andersson et al. 3
lead to incomplete processing. Proinsulin is processed by
PC1/3 at the B-chain/C-peptide junction followed by PC2
cleavage at the C-peptide/A-chain junction while PC1/3 and
PC2 processing of proIAPP results in the removal of the
C-terminal and N-terminal ﬂanking peptides, respectively
[30]. In vitro, IAPP is one of the more aggregation-
prone amyloid peptides known and insulin has been shown
to exert a concentration-dependent inhibitory eﬀect on
IAPP ﬁbril formation at neutral pH. We have produced
human IAPP and partially processed proIAPP, lacking the
C-terminal ﬂanking peptide (NIAPP) with recombinant
technology [31]. In the following, previously unpublished
study, IAPP or NIAPP (20μM) and insulin (40μM) were
dissolved in 25mM phosphate buﬀer with 50mM glycine
at pH 7 and pH 5.2. Aliquots were analyzed for the
presence of amyloid ﬁbrils after Congo red staining. We
conferred our earlier ﬁndings that addition of insulin to
IAPP delays ﬁbril formation at pH 7.0 and this was also
true for NIAPP. However, at pH 5.2 the ﬁbril formation
was triggered for both IAPP and NIAPP. Semiquantitative
analysis of amyloid amount, based on Congo red staining
and electron microscopical analyses, showed that NIAPP
was more prone to form amyloid-like ﬁbrils than mature
IAPP. Since both NIAPP and the des 32-33 C-peptide-
A-chain proinsulin derivative are expected to appear in
the secretory granules as a consequence of reduced PC2
processing, we also expressed des 32-33 C-peptide-A-chain
proinsulin. NIAPP and 32-33 C-peptide-A-chain proinsulin
were solubilized as described above and mixed 1:1 and 1:4.
It was then shown that addition of 32-33 C-peptide-A-
chain proinsulin to NIAPP promotes ﬁbril formation. These
previously unpublished results show that the intragranular
composition of prohormones and processing metabolites
is of importance and changes of the equilibrium can be
a factor that causes IAPP to aggregate. Transfection of
human proIAPP to cell lines missing one or both of the
processing enzymes has supported this conclusion since the
aberrant processing resulted in increased amyloid formation
[32, 33].
3. INFLUENCE OF HYPERGLYCEMIA ON
GRAFTED HUMAN ISLETS
3.1. Electronmicroscopicalappearance
In general, the ultrastructure of human islets grafted into
normoglycemic mice remains normal 4 weeks after implan-
tation [34]. The β-cells are in great majority. A 4-week
hyperglycaemic period induces well-known signs of β-cell
hyperactivity such as marked degranulation and also signs
of the development of an abundant rough endoplasmic
reticulum (Figure 2).Wealsoobservedsignsofglycogenpar-
ticlesaccumulatingintheβ-cells.Theseglycogendepositions
disappear when transferring the islets to a normoglycemic
milieu by curing the recipient by means of implantation of
a second islet graft. Interestingly, the mitochondria residing
in the hyperglycaemic, noncured recipients are often swollen
(Figure 2).
μm
Figure 2: Electron micrograph of human islets transplanted under
the kidney capsule of an alloxan-diabetic athymic nude mouse four
weeks after implantation. Note the extensive degranulation, the
abundant endoplasmic reticulum (star), glycogen particles (black
arrows), and swollen mitochondria (white arrow).
Taken together, these previous ultrastructural investiga-
tions show that the transmission electron microscopical tool
is of utmost importance when elucidating the impact of
diﬀerent functional loads put on human islets. Obviously,
the knowledge on the classical “hydropic degeneration,”
later referred to as “ballooning degeneration” described by
Weichelbaum and Stangl, Allen, Toreson, and Lazarus and
Volk [35], in reality has become extended by the ﬁndings
of the glycogen accumulations described above. Likewise,
the very early reports on hyalinization of the islets of
patients with diabetes by Opie, in 1901 [3], have formed
the platform for extensive studies, both morphological
and biochemical, on the formation of amyloid deposits
(described below).
3.2. Functionalproperties
The ultrastructural ﬁndings were corroborated by measure-
ments of the islet graft insulin content (Figure 3). Thus,
the high glucose-exposed islet grafts contained about one
tenth of the insulin found in the normoglycemic control
grafts indicating a parallelism between low insulin content
and extensive β-cell degranulation. In graft perfusion exper-
iments, where test substances were infused via the renal
artery and eﬄuents collected from the ureter and renal vein
[36], we found that a high glucose challenge in the test
medium increased the insulin concentration of the eﬄuent
medium in a biphasic mode when the graft had resided in
a normoglycemic recipient not treated with alloxan. Quite
in contrast, islet grafts exposed to a high (more than 20mM)
glucoseconcentrationinvivofor4weeksdisplayedablunted
insulin secretion. In fact, the integrated area under the
curve, that is, the amount of insulin secreted during the
30-minute stimulation period, was less than 5% of that
observed for the control, normoglycemic grafts (Figure 3).
Interestingly, this extensively impaired glucose-stimulated
insulin secretion was only marginally returned to normal
after a 2-week period of normoglycemia eﬀected by a second4 Experimental Diabetes Research
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Figure 3: Total insulin secretion in eﬄuent medium collected
fromhumanisletgraft-bearingkidneysduring30-minuteperfusion
with 16.7mM glucose (black bars), and insulin content of renal
subcapsular islet grafts (grey bars). Values are means ± SEM.
intrasplenic mouse islet graft (Figure 3). This was despite a
nearly total reconstitution of the insulin content of the graft.
In further studies of this defective glucose-induced
insulin release of the human islet grafts, we found that
also arginine-stimulated secretion was heavily impaired
[37]. Neither impaired glucose metabolism nor decreased
(pro)insulin biosynthesis could explain the deleterious
eﬀects of the diabetic state on human islet graft insulin secre-
tion. It is tempting to speculate that formation of intracellu-
lar amyloid deposits might be one hitherto neglected reason
forthis functional impairment. With our present knowledge,
attention should be paid to functional abnormalities also in
IAPP biosynthesis and secretion. One process of particular
interest in this context might be the enzymatic cleavage of
p r o - I A P Pb yt h ec o n v e r t i n ge n z y m e sP C2a n dP C1 / 3[ 38].
4. AMYLOID DEPOSITS IN TRANSPLANTED
PANCREATIC ISLETS INFLUENCE OF
IMPLANTATION SITE, FUNCTIONAL ACTIVITY,
AND MICROENCAPSULATION
In our ﬁrst report on the rapid deposition of amyloid in
human islets transplanted into nude mice, our primary
aim was to study the occurrence of IAPP-positive cells in
the grafts [39]. Not surprisingly, comparisons of adjacent
human islet graft sections stained for insulin and IAPP,
respectively,indicatedthattheantiserastainedthesamecells.
However, while the insulin staining was fairly even, both
strongly and weakly labelled cells occurred after staining
for IAPP. Interestingly, we found a lower percentage of
IAPP-positive cells in the grafts of hyperglycaemic mice,
suggesting that the storage of the substance was decreased
after hyperglycemia.
By means of Congo red staining, we found amyloid
deposits in human islet transplants in six out of eight nor-
moglycaemic and two out of four hyperglycaemic recipients.
All these islet grafts had resided under the kidney capsule of
the nude mice for no more than two weeks, demonstrating
the rapidity of the process. Thus, no amyloid was found
in sections of the donor pancreata collected before they
were processed for islet isolation. The amyloid deposits
were usually multiple and small and located extracellularly
but some faintly stained deposits were also found in the
cytoplasm of the islet cells.
Electron microscopical investigations showed explicitly
that IAPP immunoreactivity normally was conﬁned to the
secretory granules of the β-cells, while α-a n dδ-cells were
negative. Moreover, as in the light microscopical study,
accumulation of amyloid material, strongly labelled with
antisera to IAPP, was found in eight of the twelve grafted
mice (Figures 4(a) and 4(b)). Large amounts of amyloid
ﬁbrilswereeasilyrecognized(Figure 4(c))butsometimesthe
material also had a granular appearance.
It is worthy of note that in a comparative study
elucidating the amyloid deposition in islets of transgenic
mice expressing hIAPP and in human islets implanted into
nude mice, we found considerable diﬀerences [27]. Thus,
in human islets amyloid was mainly formed intracellularly
(Figure 4), whilst in islets from transgenic mice the amyloid
was exclusively deposited extracellularly. Later studies have
shown, however, that also in these animals the ﬁrst amyloid
occurs within β-cells [38].
Descriptionsofamyloidformationingraftedisletsinthis
paper have all referred to studies using the subcapsular renal
space as implantation site. Since essentially all clinical islet
transplantations are performed by intraportal infusion, we
were interested in investigating intraportally grafted islets as
well. Again, nude mice were used as recipients and indeed
amyloid exhibiting aﬃnity for Congo red was found in 8 of 9
islet-containinglivers(atotalof10micewereimplantedwith
human islets) [28]. Both quantitatively and qualitatively,
the formation of amyloid seemed to occur to the same
extent and similarly to that seen in the subcapsularly
grafted islets. Separate studies of intrasplenic islet grafts
showed that also such islets contained amyloid with the
same appearance as in the intraportally implanted human
islets.
W h i l ew ew e r eu n a b l et od e m o n s t r a t ea ne ﬀect of
hyperglycemia on the amount of amyloid formed in our
ﬁrst study when using both normoglycemic and alloxan-
diabetic recipients long-term (14d) culture of the human
islets prior to transplantation seemed to considerably
enhance the amyloid formation [28]. At least this was
the case in specimens observed for a short-time period—
the grafts were evaluated already after 2 weeks. Taken
together with results from studies of grafts kept under
the kidney capsule for half a year [28] where rather
large extracellular deposits were found, it appears that the
ﬁrst amyloid is formed intracellularly and that amyloid
at a later stage acts as a nidus for further extracellular
deposition. For some reason, however, the process halts
and therefore the heavy amyloid deposition as seen in
the islets of type 2 diabetes patients never develops. The
reasons for this are still unknown but obviously the present
experimental model oﬀers unique opportunities for such
studies.
One circumstance that might explain the rapid deposi-
tion of amyloid in the grafted islets is their fairly low vascular
density as compared with the endogenous islets in the
pancreas [40]. Such a relative lack of blood vessels providingArne Andersson et al. 5
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Figure 4: Intra- and extracellular amyloid in an islet graft
implanted under the renal capsule of a nude mouse. (a) In the
overview,itisseenthattheamyloid(arrow)ispresentintheperiph-
ery of degranulated β-cells (star). (b) At higher magniﬁcation, it
is obvious that the amyloid forms a network, presumably due to
presence in the endoplasmic reticulum. (c) At high magniﬁcation,
the ﬁbrillar ultrastructure of the amyloid is evident as well as its
speciﬁc immunolabelling with antibodies against IAPP, visualized
with 10nm gold particles.
20μm
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Figure 5: Polarized light microscopic image of a Congo red stained
microencapsulated human islet residing in the renal subcapsular
space of an athymic nude mouse for four weeks. The black arrow
points out amyloid in and outside a normal islet cell, whereas the
white arrow indicates amyloid in the central necrotic part of the
islet. Surrounding the islet is the alginate capsule (AC), and in the
lower part of the image the renal capsule (RC).
for an eﬃcient export of the secretory products thus might
facilitate the accumulation of IAPP and formation of amy-
loid.Theultimatetestofthathypothesiswouldbetolookfor
the presence of amyloid deposits in microencapsulated islets,
which exemplify a totally nonvascularized islet graft. For
that purpose, we encapsulated both human islets and hIAPP
transgenic mouse islets in a high-guluronic alginate solution
[41]. These capsules were subsequently transplanted into the
renal subcapsular space of normoglycemic nude mice [42].
Indeed, preliminary results suggest that encapsulated human
islet grafts that were retrieved one month after implantation
contained considerable amounts of amyloid (Figure 5).
Obviously, under these speciﬁc conditions amyloid deposits
develop, thus demonstrating that a sustained blood supply
is not a prerequisite for their formation. It also seems
feasible to use the microencapsulated islets as a tool for more
detailed studies of the amyloid formation process under
forced circumstances.
5. CLINICAL IMPLICATIONS
At present, reports on the pathology of clinically grafted
islets are very scarce and to our knowledge amyloid has not
been looked for speciﬁcally except for our recent study [43].
There are methodological diﬃculties, one of which might
be the fairly long ischemic periods before liver tissue can
be harvested. Nevertheless, studies aiming at the localization
and characterization of the implanted islets are highly
warranted. Since the identiﬁcation of the amyloid material
is often laborious, consultations with groups experienced
in this ﬁeld of research might be desirable. During the
ﬁnal preparation of this manuscript, we published data
indeed demonstrating widespread amyloid deposition in
clinically transplanted human islets [43]. A patient with type
1 diabetes for more than 35 years died in a myocardial6 Experimental Diabetes Research
infarction 5 years after the ﬁrst of three intraportal islet
infusions. In almost every second of a total of 89 islets
found in the liver tissue blocks, amyloid deposits, most of
them being extracellular, were identiﬁed. Immunoelectron
microscopy demonstrated amyloid ﬁbrils that were positive
for antibodies against IAPP. Indeed, these ﬁndings highly
strengthen the validity of our hypothesis.
6. FUTURE PERSPECTIVES
Long-term results with clinical islet transplantation are fairly
discouraging. There is evidence to suggest that this is caused
by a progressive loss of the grafted β-cells. Knowledge on
the nature of that process is, however, meagre. Therefore,
the importance of performing necropsies of as many as
possible of deceased patients with islet grafts, functioning or
nonfunctioning, cannot be enough underlined. Pathologists,
experienced in diﬀerent aspects of islet pathology, includ-
ing islet amyloidosis, should be consulted when judging
the harvested material. By such means, further insights
on the nature of the destructive process(es) should be
gained.
As regards, the pathogenic mechanisms of islet amy-
loidosis, islet transplantation models might oﬀer unique
possibilities to study them in more detail. We have very
much focussed on the ﬁrst intracellular IAPP aggrega-
tion and the role of proIAPP and proIAPP intermedi-
ates in that process. It remains to be established that
under circumstances when concentrations of such molecules
are high, there is an enhanced amyloid formation in
vivo.
In the Edmonton protocol, preparative islet culture was
not used perhaps because such manoeuvres might decrease
the viability of the isolated islets. Although that view is
controversial, it cannot be ruled out that amyloid develops
during culture of human islets or mouse islets transgenic
for hIAPP. Indeed, there is some evidence in support of
that view [28, 44]. However, it has to be proven that such
pretransplant deposits indeed stimulate a further and more
extensive formation of amyloid in the islets once they have
become transplanted.
Finally,itisstillanopenquestionastowhetherenhanced
insulin production, as under hyperglycemic conditions,
promotes amyloid growth in the transplanted islets. A
general suppression of β-cell function by means of insulin
treatment or, at least under experimental conditions, drugs
like somatostatin and its analogs or diazoxide might be
of value to test. In this context, other types of medical
intervention against IAPP aggregation should be of interest
as well. One such substance is eprodisate, which recently was
shown to slow the decline of renal function in patients with
AA amyloidosis [45].
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